Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Voci

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The Lancet. Haematology|July 2, 2022
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trialStefano Barco, Davide Voci, Ulrike Held, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|February 8, 2022
Transient perivascular inflammation of the carotid artery (TIPIC) syndromeEvy Micieli, Davide Voci, Nicola Mumoli, et al.
Thrombosis Research|November 17, 2022
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trialDavide Voci, Andrea Götschi, Ulrike Held, et al.
The American Journal of Cardiology|March 23, 2022
Effect of Chronic Kidney Disease on 5-Year Outcome in Patients With Heart Failure and Secondary Mitral Regurgitation Undergoing Percutaneous MitraClip InsertionAntonio Sisinni, Andrea Munafò, Carlo Andrea Pivato, et al.
The American Journal of Cardiology|December 28, 2020
Prognostic Value of Pre-operative Atrial Fibrillation in Patients With Secondary Mitral Regurgitation Undergoing MitraClip ImplantationCosmo Godino, Antonio Sisinni, Carlo Andrea Pivato, et al.
Thrombosis Research|August 25, 2023
Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trialsStefano Barco, Saverio Virdone, Andrea Götschi, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The Lancet. Haematology|July 2, 2022
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trialStefano Barco, Davide Voci, Ulrike Held, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|February 8, 2022
Transient perivascular inflammation of the carotid artery (TIPIC) syndromeEvy Micieli, Davide Voci, Nicola Mumoli, et al.
Thrombosis Research|November 17, 2022
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trialDavide Voci, Andrea Götschi, Ulrike Held, et al.
The American Journal of Cardiology|March 23, 2022
Effect of Chronic Kidney Disease on 5-Year Outcome in Patients With Heart Failure and Secondary Mitral Regurgitation Undergoing Percutaneous MitraClip InsertionAntonio Sisinni, Andrea Munafò, Carlo Andrea Pivato, et al.
The American Journal of Cardiology|December 28, 2020
Prognostic Value of Pre-operative Atrial Fibrillation in Patients With Secondary Mitral Regurgitation Undergoing MitraClip ImplantationCosmo Godino, Antonio Sisinni, Carlo Andrea Pivato, et al.
Thrombosis Research|August 25, 2023
Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trialsStefano Barco, Saverio Virdone, Andrea Götschi, et al.
Pageof 3